U.S. markets open in 5 hours 53 minutes
  • S&P Futures

    4,159.50
    +12.75 (+0.31%)
     
  • Dow Futures

    32,863.00
    +106.00 (+0.32%)
     
  • Nasdaq Futures

    13,285.50
    +56.75 (+0.43%)
     
  • Russell 2000 Futures

    1,927.80
    +6.00 (+0.31%)
     
  • Crude Oil

    90.01
    +1.00 (+1.12%)
     
  • Gold

    1,794.00
    +2.80 (+0.16%)
     
  • Silver

    20.05
    +0.20 (+1.02%)
     
  • EUR/USD

    1.0208
    +0.0021 (+0.20%)
     
  • 10-Yr Bond

    2.8400
    0.0000 (0.00%)
     
  • Vix

    21.74
    +0.30 (+1.40%)
     
  • GBP/USD

    1.2106
    +0.0035 (+0.29%)
     
  • USD/JPY

    135.0840
    +0.1140 (+0.08%)
     
  • BTC-USD

    23,785.63
    +765.68 (+3.33%)
     
  • CMC Crypto 200

    552.63
    +17.40 (+3.25%)
     
  • FTSE 100

    7,475.07
    +35.33 (+0.47%)
     
  • Nikkei 225

    28,249.24
    +73.37 (+0.26%)
     

Prothena to Report Second Quarter 2022 Financial Results on August 8th

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Prothena Corporation plc
Prothena Corporation plc

DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today that it will report its second quarter and first six months of 2022 financial results on Monday, August 8, 2022 after the close of the U.S. financial markets.

Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on August 8.

About Prothena

Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.

Contacts:

Investors
Jennifer Zibuda, Director, Investor Relations & Communications
650-837-8535, jennifer.zibuda@prothena.com

Media
Eric Endicott, Senior Vice President, Corporate Affairs
650-448-3670, eric.endicott@prothena.com